1 – 6 of 6
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2023
-
Mark
Local Treatment of Recurrent Renal Cell Carcinoma May Have a Significant Survival Effect Across All Risk-of-recurrence Groups
(
- Contribution to journal › Article
- 2022
-
Mark
European Association of Urology Guidelines on Renal Cell Carcinoma : The 2022 Update
(
- Contribution to journal › Scientific review
- 2021
-
Mark
Tumor Subtyping : Making Sense of Heterogeneity with a Goal Toward Treatment
(
- Contribution to journal › Scientific review
-
Mark
Updated European Association of Urology Guidelines on Renal Cell Carcinoma : Nivolumab plus Cabozantinib Joins Immune Checkpoint Inhibition Combination Therapies for Treatment-naïve Metastatic Clear-Cell Renal Cell Carcinoma
(
- Contribution to journal › Article
-
Mark
The 2021 Updated European Association of Urology Guidelines on Renal Cell Carcinoma : Immune Checkpoint Inhibitor–based Combination Therapies for Treatment-naive Metastatic Clear-cell Renal Cell Carcinoma Are Standard of Care
(
- Contribution to journal › Debate/Note/Editorial
- 2020
-
Mark
European Task Force on Atopic Dermatitis (ETFAD) statement on severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2)-infection and atopic dermatitis
(
- Contribution to journal › Letter